SERA (Sera Prognostics Inc.) Market Value to Book Value Ratio

Official company branding of seraprognostics.com (SERA)

Sera Prognostics (SERA) management is implementing advanced methods for predicting pregnancy pathologies through active collaboration with insurance providers. The current strategic direction is based on the mass market rollout of blood biomarker analysis systems to assess the risks of preterm birth. Effective molecular diagnostics management and test transparency ensure the 1.35 metric. This asset price chart below clearly demonstrates the dynamics of this biotechnology business.

SERA - Sera Prognostics Market-to-Book Ratio over the range 07/04/2022 - 10/26/2026

Financial and market metric breakdowns for Sera Prognostics Inc. (SERA)

- price and consensus price forecast:
Stock Price Sera Prognostics, Inc.|SERA - Analyst Consensus Forecast
- market capitalization data:
Market Value Sera Prognostics|SERA - Value Adjusted for Debt and Cash
- book capitalization data:
Book Value per Share Sera Prognostics|SERA - Total Stockholders' Equity|Market Value to Book Value Ratio seraprognostics.com|SERA - Total Asset Value of Company
- debt and liquidity data:
Debt to Equity Sera Prognostics|SERA - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Sera Prognostics|SERA - Company Cumulative Debt|Debts to Book Capitalization Sera Prognostics
Initial company analysis:SERA, Sera Prognostics, Inc.
Original product of Sera Prognostics

The commercial implementation of diagnostic tests by Sera Prognostics (SERA) determines future liquidity inflows, rendering the current asset value secondary to growth potential. This metric of market valuation exceeding book value measures the market premium on capital: a rising trend signals investor optimism, while a decline reflects a loss of confidence in the business's fundamental stability.

Main competitors

NTRA: Market Capitalization to Book Value Ratio|HUMA (humacyte.com) - Market Capitalization to Book Value Ratio